BFLY

Rating neutralAI Memo

Butterfly Network

As of 2026-05-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 beat and full-year reaffirmation improved near-term credibility • 2026-05-31

Expected move: -17%

Biggest risk

The bear case is that much of the better Q1 mix came from higher-margin embedded and software contributions rather than broad-based proof that the core handheld-ultrasound franchise has fully inflected, while concentration and ongoing losses mean any delayed commercialization can quickly pressure sentiment. [#8-K-2026-04-30] [#10-Q-2026-04-30]

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The post-earnings bull case is that Q1 showed real operating leverage: revenue grew 25%, gross margin expanded to 68.9%, adjusted EBITDA loss narrowed, and management still reaffirmed full-year guidance while outlining additional Home & Community Care, enterprise, and embedded milestones. [#8-K-2026-04-30]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-03

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Revenue concentration and still-lossmaking execution keep the setup fragile
Home & Community Care and enterprise software milestones are the clearest next growth proof points
The post-earnings bull case is that Q1 showed real operating leverage: revenue grew 25%, gross margin expanded to 68.9%, adjusted EBITDA loss narrowed, and management still reaffirmed full-year guidance while outlining additional Home & Community Care, enterprise, and embedded milestones.

BearKey bullets

Home & Community Care is still moving toward a first commercial agreement rather than operating at proven scale.
[#8-K-2026-04-30]
One customer accounted for more than 10% of Q1 2026 revenue, leaving the quarter's mix vulnerable to partner timing swings.

WatchKey bullets

Q1 beat and full-year reaffirmation improved near-term credibility

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $6 (p=45%)

Bull/Bear spread: +3% / -38%

Vs latest close: Bull +3% · Base -17% · Bear -38%

Scenario probabilities

Bull Target: $7 (p=30%)Base Target: $6 (p=45%)Bear Target: $4 (p=25%)

Commentary

This T+3 follow-up still looks like a cautious monitoring setup, but the earnings release improved the near-term tone. The immediate reaction was positive in market coverage, and the May 1, 2026 anchor close of $5.40 leaves the stock only modestly below the packet's $5.56 median target, implying some of the beat and guidance reaffirmation was absorbed quickly. The main gap is that clear delayed analyst revisions were not readily available from checked sources, so confidence should not be upgraded solely from the first post-print move. [#8-K-2026-04-30]

As of 2026-05-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Revenue concentration and still-lossmaking execution keep the setup fragile
Home & Community Care and enterprise software milestones are the clearest next growth proof points

Scenarios

Bull Target (Scenario probability)

$7 / p=30% prob

Base Target (Scenario probability)

$6 / p=45% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Price $7 as of 2026-07-17

Nearest Scenario: Bull (∆ 3%)

Targets vs latest close: Bull +3% · Base -17% · Bear -38%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-31
Q1 beat and full-year reaffirmation improved near-term credibility
Butterfly's April 30, 2026 earnings release reported Q1 revenue of $26.5 million, up 25% year over year, gross margin of 68.9%, adjusted EBITDA loss of $6.1 million, and reaffirmed FY2026 revenue guidance of $117 million to $121 million while adding Q2 revenue guidance of $27 million to $31 million. That combination supports a constructive post-earnings read, but with the stock already near the median target the main question is whether the stronger print can hold through the next few weeks of digestion rather than simply produce a one-day bounce. [#8-K-2026-04-30]
Prob 75.00% • Move 10.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Revenue concentration and still-lossmaking execution keep the setup fragile
2026-08-15
The Q1 2026 10-Q shows cash and cash equivalents of $138.0 million, but the company still posted a $12.7 million net loss and one customer accounted for more than 10% of quarterly revenue. That leaves BFLY exposed if embedded licensing momentum moderates, enterprise conversions slip, or the planned Home & Community Care rollout takes longer to commercialize. [#10-Q-2026-04-30]
Prob 55% • Move -16% • Priced-in 45%

Long-term Catalysts

Months to a year

Home & Community Care and enterprise software milestones are the clearest next growth proof points
2026-09-30
Management said it is progressing toward a first Home & Community Care commercial agreement in the first half of 2026 with an initial statewide deployment expected in the third quarter, while also citing a first enterprise deal of the year and continued software pipeline growth. If those milestones convert into recurring revenue and broader workflow adoption, investors could give more weight to Butterfly's platform narrative beyond probe sales. [#8-K-2026-04-30] [#10-K-2026-02-27]
Prob 50% • Move 18% • Priced-in 35%

Risks

Home & Community Care is still moving toward a first commercial agreement rather than operating at proven scale. [#8-K-2026-04-30]
One customer accounted for more than 10% of Q1 2026 revenue, leaving the quarter's mix vulnerable to partner timing swings. [#10-Q-2026-04-30]
Peer read-through is limited because the available comp set is relatively loose and analyst coverage appears thin.
The company remains lossmaking despite better adjusted EBITDA, so continued cash use and commercialization delays still matter. [#8-K-2026-04-30] [#10-Q-2026-04-30]

Peers

Symbol	Summary
IART	Smaller hospital-facing medtech peer that is more useful for comparing commercialization discipline, margin sensitivity, and execution risk than for product similarity.
OPK	Loose small-cap healthcare technology comparator with a closer market-cap profile, helpful for framing capital-markets tolerance for uneven execution but not a direct ultrasound peer.
BSX	Large procedural-device benchmark for hospital sales motion and workflow adoption, though its scale and diversification make it an aspirational rather than direct operating comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-03

AI Stock Memo: BFLY - Butterfly Network - RankAlpha